If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
You need a JavaScript-enabled browser to view this Publication
Please follow these steps to view the Publication:
Enable JavaScript in your browser
Refresh this page
Best regards
Zmags
GASTROENTEROLOGY
EMJ Gastroenterol. 2019 Suppl 1 • europeanmedical-journal.com
INSIDE
IL-12/23 in IBD: Making the Best
Use of Available Evidence
IL-12/23 in IBD: Making the Best
Use of Available Evidence
This satellite symposium took place on 7th March 2019, as
part of the 14th Congress of the European Crohn’s and Colitis
Organisation (ECCO) in Copenhagen, Denmark
Chairperson: Alessandro Armuzzi1
Speakers: Subrata Ghosh,2 Tim Raine,3 Alessandro Armuzzi1
1. Catholic University, Rome, Italy
2. University of Birmingham, Birmingham, UK
3. Cambridge University Hospitals, NHS Foundation Trust, Cambridge, UK
Disclosure: Prof Armuzzi has received research support and has been a principal investigator
for MSD, Takeda, and Pfizer; has been a consultant for AbbVie, Allerga
GASTROENTEROLOGY EMJ Gastroenterol. 2019 Suppl 1
IL-12/23 in IBD: Making the Best Use of Avai
The second case considered a patient with bio-naï
Additionally, IM-UNITI included a nonrandomised p
However, a markedly different picture
mild-to-moderate abdominal pain and d
4, CRP 5 mg/dL, fCal 162 µg/g). Azathioprine wa
A Danish population cohort demonstrated UC to be
Many pathways have been studied in the inte
> Endoscopic improvement was achieved in 35.2
study. Digital oral presentation 2